Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (289)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (289)
Apply filters
Showing 61 to 70 of 289
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392
Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981
Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Technology appraisal guidance
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415
Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]
Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885
Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]
Technology appraisal guidance
Previous page
1
…
5
6
Current page
7
8
9
…
29
Page
7
of
29
Next page
Results per page
10
25
50
All
Back to top